ClinicalTrials.gg
CompletedNCT01197885Updated Jun 13, 2025

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

A Phase 2 interventional study of IMAB362 in Solid Tumors, sponsored by Ganymed Pharmaceuticals GmbH. Completed at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Ganymed Pharmaceuticals GmbH (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

IMAB362 is a monoclonal antibody specific for gastric or lower esophageal adenocarcinoma. Preclinically IMAB362 was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects). The aim of this phase II study is to establish efficacy and safety of multiple doses of IMAB362 as monotherapy in patients suffering from metastatic, refractory or recurrent adenocarcinoma of the stomach or the lower esophagus.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Ganymed Pharmaceuticals GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before Ganymed Pharmaceuticals GmbH became part of Astellas Pharma Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , or recurrent disease of advanced adenocarcinoma of the stomach or the lower esophagus proven by histology
  • CLDN18.2 expression of the material from the cancer confirmed by immunohistochemistry
  • At least 1 measurable site of disease according to criteria

Exclusion criteria

Exclusion Criteria:

  • Less than 3 weeks since prior chemo-or radiation therapy
  • Other concurrent anticancer therapies
  • Concurrent anticoagulation with vitamin K antagonists
  • Therapeutic doses of Heparin (prophylactic doses accepted)
  • Uncontrolled or severe illness
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    IMAB362

    Two different doses (antibody / body surface area) of IMAB362 will be administered sequentially.

    Drug: IMAB362

Interventions

  • Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less

06

What researchers measure

Primary outcomes

  1. Rate of remission (CR, PR) according to RECIST Criteria

    Time frame: All patients will be evaluated in 8-12 weeks intervals until 6 months after last infusion

Secondary outcomes

  1. Number of Participants with adverse events as a measure of safety and tolerability

    Time frame: All patients will be evaluated in 8-12 weeks intervals until 6 months after last infusion

  2. Frequency and severity of adverse events according to CTCAE v3.0

    Time frame: All patients will be evaluated in 8-12 weeks intervals until 6 months after last infusion

  3. Progression-free-survival time (PFS)

    The time from start of the first infusion to date of first observed disease progression or death due to progression (whichever is first)

    Time frame: All patients will be evaluated in 8-12 weeks intervals until 6 months after last infusion

07

Study locations

21 sites
  • Oncology Dispensary "Dr. Marko Markov"
    Varna, 9002, Bulgaria
  • MHAT "St.Marina"
    Varna, 9010, Bulgaria
  • Complex Oncology Center
    Veliko Turnovo, 5000, Bulgaria
  • Charité - Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Medizinische Univeritätsklinik Ruhr-Universität Bochum
    Bochum, 44892, Germany
  • Klinikum Braunschweig
    Braunschweig, 38114, Germany
  • Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
    Essen, 45122, Germany
  • Krankenhaus Nordwest, Klinik für Onkologie und Hämatologie
    Frankfurt, 60488, Germany
  • Universitätsklinikum Halle
    Halle, 06120, Germany
  • Universitäres Cancer Center Universitätsklinikum Eppendorf
    Hamburg, 20246, Germany
  • Onkologische Schwerpunktpraxis Eppendorf
    Hamburg, 20249, Germany
  • Universitätsklinikum Heidelberg, NCT
    Heidelberg, 69120, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • Universitätsmedizin der Johannes-Gutenberg Universität
    Mainz, 55101, Germany
  • Klinikum rechts der Isar
    Muenchen, 81675, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Piejuras Hospital
    Liepaja, Latvia
  • Paula Stradina Clinical University Hospital
    Riga, 1002, Latvia
  • Riga East Clinical Research
    Riga, 1038, Latvia
  • Vilnius University
    Vilnius, 08660, Lithuania
  • Kantonsspital St. Gallen
    St.Gallen, 9007, Switzerland
08

References and documents

Publications

  • Tureci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. PubMed 31240302 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2010 to primary completion in Aug 2015, 59 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2010
First posted
Sep 9, 2010
StartActual
Sep 3, 2010
Primary completionActual
Aug 13, 2015
CompletionActual
Aug 13, 2015
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01197885
Responsible party
Sponsor
First posted
Sep 9, 2010
Start date
Sep 3, 2010
Primary completion
Aug 13, 2015
Completion
Aug 13, 2015
Last update
Jun 13, 2025

Study contacts

Martin Schuler, Prof. Dr. med.
principal investigator · Innere Klinik Universitätsklinikum Essen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion